Tour Kite’s CAR T-cell Therapy Manufacturing Facility in Europe

As the leader in cell therapy, Kite’s manufacturing facility in the Netherlands allows us to ensure patients who are eligible for CAR T-cell therapy can receive it as quickly as possible, no matter their location. Opened in 2020, this facility nearly doubled Kite’s production capacity and made it faster to provide treatment for patients in Europe and surrounding areas.
For more information about CAR T-cell therapy, visit:
Website: www.kitepharma.com
Twitter: / kitepharma
Facebook: / kiteagileadcompany
LinkedIn: / kite-pharma-inc-